Aquestive Therapeutics Hit With Securities Fraud Lawsuit Over FDA Approval Misrepresentations
$AQST plummets 37% after FDA rejects Anaphylm application. Investors sue over alleged misleading statements about approval prospects.
AQSTsecurities fraudclass action lawsuit